Despite raised analyst confidence driven by positive clinical momentum for Zanidatamab and anticipated catalysts, Zymeworks’ consensus analyst price target has been modestly lowered from $21.05 to $20.06.
Analyst Commentary
- Positive momentum for Zanidatamab in biliary tract cancer.
- Upcoming HERIZON study data release in late Q4 viewed as a catalyst.
- Evidence of growing market traction for key pipeline asset.
- Raised confidence in clinical and commercial progress.
- Bullish analysts anticipating further upside based on near-term catalysts.
What's in the News
- Zymeworks voluntarily discontinued clinical development of ZW171 after Phase 1 due to benefit-risk concerns for monotherapy, while progressing pipeline assets ZW191 (Phase 1 recruiting) and ZW251 (clinical trials expected in 2025).
- Zanidatamab, partnered with BeOne Medicines and Jazz Pharmaceuticals, received accelerated/conditional regulatory approvals in the U.S., Europe, and China for HER2-positive biliary tract cancer and is under investigation in multiple global trials.
- The FDA cleared the IND for ZW251 (a GPC3-targeted ADC for liver cancer), which showed promising preclinical results, with clinical trial initiation expected in 2025.
- Zymeworks entered a private placement to issue 415,000 shares at $12.02 per share, raising approximately $5 million with no underwriting fees.
- Zymeworks shifted from several Russell Value Indexes to inclusion in multiple Russell Growth Indexes during recent benchmark reconstitutions.
Valuation Changes
Summary of Valuation Changes for Zymeworks
- The Consensus Analyst Price Target has fallen slightly from $21.05 to $20.06.
- The Net Profit Margin for Zymeworks has significantly fallen from 16.06% to 14.17%.
- The Future P/E for Zymeworks has risen from 97.27x to 105.05x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.